Stay updated on Durvalumab & Tremelimumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab & Tremelimumab in NSCLC Clinical Trial page.

Latest updates to the Durvalumab & Tremelimumab in NSCLC Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe record for the completed ARCTIC lung cancer trial is now available, with study details, participant criteria, treatment arms, outcome measures, and results-related resources. It also includes links to study documents and information about requesting access to individual participant data.SummaryDifference100%

- Check14 days agoChange DetectedThe footer revision identifier changed from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check21 days agoChange DetectedA site-wide banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to related updates and FAQs.SummaryDifference1%

- Check28 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2 while the study page continues to display a 403 error.SummaryDifference0.2%

- Check35 days agoChange DetectedThe footer revision label changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check56 days agoChange DetectedA new Revision: v3.7.0 is shown, and several key study documents and contact/resources have been redacted or removed from the Study Documents section, reducing access to the SAP, CSP, and related materials.SummaryDifference17%

Stay in the know with updates to Durvalumab & Tremelimumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab & Tremelimumab in NSCLC Clinical Trial page.